RESEARCH ARTICLE

Meta-analysis of Seven Randomized Control Trials to Assess the Efficacy and Toxicity of Combining EGFR-TKI with Chemotherapy for Patients with Advanced NSCLC who Failed First-Line Treatment

Bing-Kun Xiao¹, Jian-Yun Yang¹, Jun-Xing Dong¹, Zhao-Shuai Ji², Hai-Yan Si³, Wei-Lan Wang⁴*, Rong-Qing Huang¹*

Abstract

Background: Some recent clinical trials have been conducted to evaluate a combination of EGFR-TKI with chemotherapy for advanced NSCLC patients as second-line therapy, but the results on the efficacy of such trials are inconsistent. The aim of this meta-analysis was to evaluate the efficacy and safety of combination of EGFR-TKI and chemotherapy for patients with advanced NSCLC who failed first-line treatment. Materials and Methods: We searched relative trials from PubMed, EMBASE, ASCO Abstracts, ESMO Abstracts, Cochrane Library and ClinicalTrials.gov. Outcomes analyzed were overall response rate (ORR), progression-free survival (PFS), overall survival (OS) and major toxicity. Results: Seven trails eventually were included in this meta-analysis, covering 1,168 patients. The results showed that the combined regimen arm had a significant higher ORR (RR 1.76 [1.16, 2.66], p=0.007) and longer PFS (HR 0.75 [0.66-0.85], p<0.0001), but failed to show effects on OS (HR 0.88 [0.68-1.15], p=0.36). In terms of subgroup results, continuation of EGFR-TKI in addition to chemotherapy after first-line EGFR-TKI resistance conferred no improvement in ORR (RR 0.95 [0.68, 1.33], p=0.75) and PFS (HR 0.89[0.69, 1.15], p=0.38), and OS was even shorter (HR 1.52 [1.05-2.21], p=0.03). However, combination therapy with EGFR-TKI and chemotherapy after failure of first-line chemotherapy significantly improved the ORR (RR 2.06 [1.42, 2.99], p=0.0002), PFS (HR 0.71 [0.61, 0.82], p<0.00001) and OS (HR 0.74 [0.62-0.88], p=0.0008), clinical benefit being restricted to combining EGFR-TKI with pemetrexed, but not docetaxel. Grade 3-4 toxicity was found at significantly higher incidence in the combined regimen arm. Conclusions: Continuation of EGFR-TKI in addition to chemotherapy after first-line EGFR-TKI resistance should be avoided. Combination therapy of EGFR-TKI and pemetrexed for advanced NSCLC should be further investigated for prognostic and predictive factors to find the group with the highest benefit of the combination strategy.

Keywords: EGFR-TKI - chemotherapy - non-small cell lung cancer - meta-analysis - RCTs

Introduction

Lung cancer is the leading cause of cancer-related death worldwide (Jemal et al., 2010; Song., et al., 2014). Combination platinum chemotherapy has been shown to improve the survival of patients for advanced non-small-cell lung cancer (NSCLC), but the expected response rate is only approximately 30% (Schiller et al., 2002). Most patients with advanced NSCLC eventually show tumor progression after standard first-line platinum-based combination chemotherapy (Aydiner et al., 2013). Docetaxel, pemetrexed and EGFR-TKI have been approved for second-line treatment, but only about 10% of patients respond to monotherapy using any of these agents (Shepherd et al., 2000; Hanna et al., 2004; Kim et al., 2008; Di Maio et al., 2009). EGFR-TKI is a potent tyrosine kinase inhibitor of epidermal growth factor receptor, which is recommended as first-line therapy in patients with advanced NSCLC who have known active sensitizing EGFR mutation (Linardou et al., 2009; Dahabreh et al., 2010).

A recent meta-analysis showed that combination of EGFR–TKIs and chemotherapy leads to progression-free survival (PFS) benefit as first-line treatment for advanced NSCLC, regardless of EGFR-mutation status, but has no demonstrable impact on OS (Yang et al., 2013). However, it did not explore the effect of combination therapy mainly pemetrexed-based therapy plus EGFR–TKI for advanced NSCLC, which showed a strong synergism in NSCLC cells regardless of the presence or absence of sensitizing...
EGFR mutations (Giovannetti et al., 2008).

Some recent clinical trials have been conducted to evaluate combination of EGFR-TKI with chemotherapy for advanced NSCLC patients as second-line therapy, but the results on the efficacy of such trials are inconsistent (Aerts et al., 2013; Halmos et al., 2013; Lee et al., 2013; Li et al., 2013; Auliac et al., 2014; Dittrich et al., 2014; Mok et al., 2014). Therefore, we conducted this meta-analysis to systematically study the efficacy and toxicity of combination of EGFR-TKI and chemotherapy for patients with advanced NSCLC who failed first-line treatment. Subgroup analysis was performed according to different first-line treatment and different chemotherapeutic agents in combination with EGFR-TKI to discuss their potential clinical applications and the better combination strategy.

Materials and Methods

Search strategy

We have collected the eligible trials by searching the PubMed, EMBASE, ASCO Abstracts, ESMO Abstracts, Cochrane Library and Clinical Trials.gov for relevant clinical trials up to September 2014. The keywords were used as follow: “erlotinib OR tarceva,” “gefitinib OR iressa”, “EGFR-TKI,” and “non small cell lung cancer OR NSCLC”. All the randomized controlled trials on combination of EGFR-TKI and chemotherapy as second-line therapy for NSCLC were collected and identified. We have also searched all reference lists from trials selected by electronic searching to look for trials that may have been overlooked.

Inclusion criteria

The randomized controlled trials (RCTs) were eligible for inclusion in our meta-analysis if combined regimen of EGFR-TKI and chemotherapy was compared with chemotherapy or EGFR-TKI monotherapy in patients with NSCLC after failure of first-line treatment. Phase I study and phase II study with only one single arm were excluded. All full of papers on original data were included. Abstracts were also included if sufficient information on study design and outcomes was available.

Data extraction and quality assessment

Two investigators independently identified eligible trials and discrepancies were resolved by an independent expert. The data collected included baseline patient characteristics: first author, year of publication, name and the timing of administration of EGFR-TKI and chemotherapy, number of patients in two arms, sex, age, race, performance status (smoking history and PS). The outcomes investigated included overall response rate (ORR), progression-free survival (PFS), overall survival (OS) and toxicities. Only grade 3 or 4 toxicities were analyzed.

The methodological quality of the studies was assessed by using the Jadad score (Jadad et al., 1996). We graded each parameter of trial quality as “good” when the score is 3 to 5.

Statistical analysis

A hazard ratio (HR) and associated 95% CIs was used for results of comparing PFS and OS in both arms. Relative risk (RR) and its 95% CI were calculated to assess ORR and grade 3 or 4 toxicities.

Heterogeneity in the results of the trials was estimated by the chi-square test, and I² index were chosen accordingly (Higgins et al., 2003). When there was no statistically significant heterogeneity, a pooled effect was calculated with a fixed-effect model. When heterogeneity was observed (p<0.1, or I²>50%), further analysis (subgroup analysis or random-effect model) was conducted to identify the potential cause. All reported p values were two-sided and p values less than 0.05 were regarded as statistically significant. All meta-analysis were performed by Review Manager 5.2.

Results

Characteristics of the included trials

We reviewed 1639 potentially relevant trials from our initial search strategies. After exclusion of duplicate and irrelevant studies, seven trials were highly eligible for inclusion in this meta-analysis. Of the included studies, two studies compared continuation of EGFR-TKI in addition to chemotherapy vs chemotherapy after progression on first-line EGFR-TKI (Halmos et al., 2013; Mok et al., 2014), five studies compared EGFR-TKI plus chemotherapy vs chemotherapy or EGFR-TKI alone after progression on first-line chemotherapy (Aerts et al., 2013; Lee et al., 2013; Li et al., 2013; Auliac et al., 2014; Dittrich et al., 2014). The study search process is shown in a flow chart (Figure 1). Baseline characteristics of the seven trials are provided in Table 1.

Jadad score was used to assess the quality of the included trials. Overall, six studies scored 3, one scored 5.

Overall response rate

All the 7 trials reported outcome of ORR. The pooled RR for ORR showed that EGFR-TKI plus chemotherapy as second-line therapy significantly improved the ORR (RR 1.76 [1.16, 2.66], p=0.007), based on the random effects model, due to significant heterogeneity (I²=62%). Subgroup analyses were performed according to different first-line therapy. Significant ORR improvement was observed in the combined regimen of TKI and chemotherapy group after progression on first-line chemotherapy (RR 2.06 [1.42, 2.99], p=0.0002), but not...
improvement in continuation of EGFR-TKI addition to chemotherapy group after progression on first-line TKI (RR 0.95 [0.68, 1.33], p=0.75) (Figure 2).

Progression-free survival (PFS)

All 7 trials included in the analysis provided PFS results. Compared to chemotherapy or EGFR-TKI alone, the combination of TKI and chemotherapy resulted in statistically significant improvement in PFS (HR 0.75 [0.66-0.85], p<0.00001), without apparent heterogeneity among the studies (I²=0.11, F=40%).

Subgroup analysis showed that the beneficial effect was restricted to the combined regimen of TKI and chemotherapy arm after progression on first-line chemotherapy (HR 0.71 [0.61, 0.82], p<0.00001), whereas continuation of EGFR-TKI addition to chemotherapy arm after progression on first-line TKI did not show a significant difference compared with TKI or chemotherapy alone (HR 0.89 [0.69, 1.15], p=0.38) (Figure 3).

In addition, we took further subgroup analyses in patients with advanced NSCLC who failed first-line chemotherapy to define potentially benefit from different chemotherapeutic agents in combination with EGFR-TKI(Aerts et al., 2013; Lee et al., 2013; Li et al., 2013; Auliac et al., 2014; Dittrich et al., 2014). Results showed that PFS improvement was only observed in combining pemetrexed with EGFR-TKI group (HR 0.63 [0.53, 0.74], p=0.00001), whereas docetaxel with EGFR-TKI group did not show significant improvement in PFS (HR 1.01 [0.77, 1.34], p=0.92) (Figure 4).

Overall survival (OS)

Just 6 trials on the data of OS were available. The trial by Auliac et al. didn’t give the HRs, associated 95%CIs or survival curves for OS (Auliac et al., 2014). There was no significant difference between the combined regimen arm and monotherapy arm (HR 0.88 [0.68-1.15], p=0.36).

Nevertheless, there might be substantial heterogeneity in the HRs for OS from the individual trials (p=0.02, F=661%) and we incorporated it into random-effects model.

Results were inconsistent when subgroup analyses

Table 1. Characteristic of the Seven Eligible Randomized Trails in this Meta-analysis

<table>
<thead>
<tr>
<th>Authors and year</th>
<th>Phase</th>
<th>Regimens(per arm)</th>
<th>Patients</th>
<th>Male (%)</th>
<th>Median age</th>
<th>Smoker (%)</th>
<th>Race(%)</th>
<th>ECOG PS 0/1(%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dittrich et al 2014</td>
<td>II</td>
<td>Pem(d1)+Erl(daily), q3w</td>
<td>76</td>
<td>46(61)</td>
<td>64</td>
<td>86.8</td>
<td>&lt;2%</td>
<td>66(88)</td>
</tr>
<tr>
<td>Lee et al 2013</td>
<td>II</td>
<td>Pem(d1)+Erl(d2-14), q3w</td>
<td>83</td>
<td>49(59)</td>
<td>61</td>
<td>83</td>
<td>&lt;2%</td>
<td>72(86.8)</td>
</tr>
<tr>
<td>Aerts et al 2013</td>
<td>II</td>
<td>CT (d1), q3w</td>
<td>82</td>
<td>28(34)</td>
<td>53</td>
<td>9</td>
<td>49(60)</td>
<td>76(92.7)</td>
</tr>
<tr>
<td>Aerts et al 2013</td>
<td>II</td>
<td>CT (d1)+Erl(d2-16), q3w</td>
<td>116</td>
<td>73(63)</td>
<td>62.5</td>
<td>97(84)</td>
<td>NR</td>
<td>133(100)</td>
</tr>
<tr>
<td>Li et al 2013</td>
<td>II</td>
<td>Pem(d1)+Erl(d2-17), q3w</td>
<td>74</td>
<td>54(67)</td>
<td>59.7</td>
<td>72(97)</td>
<td>NR</td>
<td>61(82)</td>
</tr>
<tr>
<td>Mok et al 2014</td>
<td>III</td>
<td>Gef(daily)+Pem(d1)+Cis(d1), q3w</td>
<td>133</td>
<td>46(35)</td>
<td>59</td>
<td>45(34)</td>
<td>NR</td>
<td>133(100)</td>
</tr>
<tr>
<td>Auliac et al 2014</td>
<td>II</td>
<td>Pem(d1)+Erl(d2-17), q3w</td>
<td>27</td>
<td>14(52)</td>
<td>64</td>
<td>22(81)</td>
<td>0(0)</td>
<td>24(89)</td>
</tr>
<tr>
<td>Auliac et al 2014</td>
<td>II</td>
<td>Doc(d1), q3w</td>
<td>80</td>
<td>35(44)</td>
<td>55.9</td>
<td>0(0)</td>
<td>43(54)</td>
<td>76(95.0)</td>
</tr>
<tr>
<td>Li et al 2013</td>
<td>II</td>
<td>Pem(d1)+Erl(d2-14), q3w</td>
<td>83</td>
<td>20(26)</td>
<td>55.8</td>
<td>0(0)</td>
<td>41(53)</td>
<td>71(91.0)</td>
</tr>
<tr>
<td>Lee et al 2013</td>
<td>II</td>
<td>Pem(d1)+Erl(d2-17), q3w</td>
<td>24</td>
<td>5(21)</td>
<td>67</td>
<td>41(55)</td>
<td>0(0)</td>
<td>76(92.7)</td>
</tr>
</tbody>
</table>


Figure 2. Comparison TKIs plus CT with TKIs or CT Alone as Second-line Therapy in ORR (random-effects model).

Figure 3. Comparison TKIs vs CT Alone as Second-line Therapy in PFS (fixed-effect model).

Figure 4. Comparison TKIs plus CT with TKIs or CT Alone as Second-line Therapy in OS (fixed-effect model).
group (HR 0.75 [0.63, 0.90], p=0.002) (Figure 6).

**Toxicities**

This meta-analysis assessed the toxicities with grade 3 or 4 toxicities of EGFR-TKI with chemotherapy vs. EGFR-TKI or chemotherapy group. The analysis showed the combined regimen caused more grade 3 or 4 anemia (RR 1.73 [1.11, 2.69], p =0.01) (p=0.09, I² =45%), leukopenia (RR 3.51 [2.25, 5.50], p<0.00001) (p=0.18, I²=34%), neutropenia (RR 1.79 [1.32, 2.42], p=0.0002) (p=0.04, I²=55%), thrombocytopenia (RR 2.59 [1.12, 6.00], p=0.03) (p=0.27, I²=24%), rash (RR 2.78[1.55,4.98], p=0.0006) (p=0.32, I²=15%), diarrhoea

**Publication bias**

To minimize the publication bias, we selected papers strictly according to inclusion criteria. Furthermore, publication bias was detected by funnel plot. No apparent publication bias was found in the analysis.

**Discussion**

About 40–50% NSCLC patients will receive second-line therapy after failure of first-line standard therapy (Stinchcombe and Socinski, 2009). However, available for second-line treatment options are limited: docetaxel, pemetrexed, and erlotinib (Massarelli and Herbst, 2006). Any second-line treatment should represent a rational selection of a drug or drug combination depending on their activity against tumors pretreated with distinct first-line therapies (Gandara et al., 2009). The combination of pemetrexed or docetaxel and EGFR-TKI has demonstrated synergistic or additive activity in preclinical studies. However, the results on the efficacy of several RCTs conducted to evaluate combination of chemotherapy and EGFR-TKI as second-line therapy for advanced NSCLC are inconsistent. The IMPRESS study reported...
at ESMO 2014 congress showed that continuation of gefitinib in addition to pemetrexed/cisplatin would be of no clinical benefit for patients with NSCLC after progression on first-line gefitinib (Mok et al., 2014). And a phase II trial also showed that no benefit was seen with the continuation of erlotinib in addition to chemotherapy (docetaxel or pemetrexed) as compared to chemotherapy (docetaxel or pemetrexed) alone in patients who had previously benefited from erlotinib but then showed progression (Halmos et al., 2013). For patients with advanced NSCLC who failed first-line chemotherapy, combination of docetaxel and erlotinib as second-line was found not more effective than monotherapy in two phase II randomized trials (Aerts et al., 2013; Auliac et al., 2014). Nevertheless, combination of pemetrexed and erlotinib as second-line in four RCTs showed promising clinical activity after failure of first-line chemotherapy (Aerts et al., 2013; Lee et al., 2013; Li et al., 2013; Dittrich et al., 2014), regardless of whether concomitant or sequential combination, unselected or enriched patients. As a result, it is of particular importance to determine whether combination of EGFR-TKI and chemotherapy after failure of first-line treatment would increase clinical activity. The results of our meta-analysis showed that the combined regimen arm resulted in a significant higher ORR (RR 1.76 [1.16, 2.66], p = 0.007) and longer PFS (HR 0.75 [0.66-0.85], p < 0.00001), but failed to show OS improvement (HR 0.88 [0.68-1.15], p = 0.36). Subgroup analysis showed that different first-line therapy resulted in different clinical effect of combination of EGFR-TKI and chemotherapy as second-line therapy. Continuation of EGFR-TKI in addition to chemotherapy at the time of EGFR-TKI resistance which was formerly chosen by many clinicians was confirmed no improvement in ORR, PFS and OS. Several factors may contribute to the negative study results, including a possible antagonism between platinum and EGFR-TKI regardless of the EGFR mutation status (Tsai et al., 2011; Goldberg et al., 2013; Tsai et al., 2013), and no enhanced antitumor effect on the growth of TKI-resistant NSCLC cells with the T790M mutation (about 50% acquisition of EGFR) for combination of EGFR-TKI and pemetrexed therapy (Takezawa et al., 2010). Of course, there are other mechanisms of resistance to EGFR TKIs, including MET amplification, HGF overexpression, PIK3CA mutations and PDGFR expression et al (Remon et al., 2014). Dynamics of resistance evolution and the question of heterogeneity add to complexity of the problem. However, we found that combination therapy with EGFR-TKI and chemotherapy after failure of first-line chemotherapy significantly improved the ORR (RR 2.06 [1.42, 2.99], p = 0.0002), PFS (HR 0.71 [0.61, 0.82], p < 0.00001) and OS (HR 0.74 [0.62-0.88], p = 0.0008), which clinical benefit was restricted to combining pemetrexed with EGFR-TKI. Many preclinical studies showed that EGFR-TKI and pemetrexed had a strong synergism in NSCLC cells, regardless of the presence or absence of sensitizing EGFR mutations. Pemetrexed may increase EGFR phosphorylation and reduce Akt phosphorylation (sensitizing tumor cells to erlotinib), while erlotinib was found to reduce thymidylate synthase expression and activity, which in turn may sensitize tumor cells to pemetrexed (Giovannetti et al., 2008). In addition, non cisplatin-based double chemotherapy in these trials may be another reason to result in clinical effect. Nevertheless, it is difficult to explain why our meta-analysis showed that combination docetaxel with EGFR-TKI after failure of first-line chemotherapy did not improve PFS (HR 1.01 [0.77, 1.34], p = 0.92) and OS (HR 0.84 [0.50, 1.41], p = 0.51), because combined EGFR-TKI and antimitotube agents showed synergism in NSCLC cells harboring no sensitizing EGFR mutations in many preclinical studies (Mahaffey et al., 2007; Tsai et al., 2012). The same negative results of combined EGFR-TKI and antimitotube agents as first-line therapy were found in TRIBUTE study (Herbst et al., 2005), INTACT -2 trial (Herbst et al., 2004), CALGB 30406 trial (Janne et al., 2012) and a randomized phase II by Hirsh et al (Hirsch et al., 2011), regardless of histology type, administration sequence, EGFR mutations status, whether patients was unselected or enriched population, and whether combining platinum or not. Thus we consider that combination antimitotube agents with EGFR-TKI may be not a good strategy for advanced NSCLC.

As expected, the combination produced more toxicity than either single agent. Grade 3 or 4 toxicities increased with combination therapy were anemia, leukopenia, neutropenia, thrombocytopenia, rash, diarrhea and febrile neutropenia. However, these side effects were generally clinically manageable.

There are several limitations in this meta-analysis. First, although the publication bias was not found by funnel plots, the small number of phase III trial and the small number of patients for inclusion limited the power of the analysis. Second, we did not perform stratification analysis for the EGFR mutations, regimen in control group or administration sequence due to small sample size or absence of original data. Third, heterogeneity among trials was found in our meta-analysis. We applied a random effect model that takes possible heterogeneity into consideration.

In conclusion, our meta-analysis showed that different first-line therapy resulted in different clinical effect of combination of EGFR-TKI and chemotherapy as second-line therapy. Continuation of EGFR-TKI after failure of first-line chemotherapy did not improve PFS (HR 2.06 [1.42, 2.99], p = 0.0002), PFS (HR 0.71 [0.61, 0.82], p < 0.00001) and OS (HR 0.74 [0.62-0.88], p = 0.0008), which clinical benefit was restricted to combining pemetrexed with EGFR-TKI. Many preclinical studies showed that EGFR-TKI and pemetrexed had a strong synergism in NSCLC cells, regardless of the presence or absence of sensitizing EGFR mutations. Pemetrexed may increase EGFR phosphorylation and reduce Akt phosphorylation (sensitizing tumor cells to erlotinib), while erlotinib was found to reduce thymidylate synthase expression and activity, which in turn may sensitize tumor cells to pemetrexed (Giovannetti et al., 2008). In addition, non cisplatin-based double chemotherapy in these trials may be another reason to result in clinical effect. Nevertheless, it is difficult to explain why our meta-analysis showed that combination docetaxel with EGFR-TKI after failure of first-line chemotherapy did not improve PFS (HR 1.01 [0.77, 1.34], p = 0.92) and OS (HR 0.84 [0.50, 1.41], p = 0.51), because combined EGFR-TKI and antimitotube agents showed synergism in NSCLC cells harboring no sensitizing EGFR mutations in many preclinical studies (Mahaffey et al., 2007; Tsai et al., 2012). The same negative results of combined EGFR-TKI and antimitotube agents as first-line therapy were found in TRIBUTE study (Herbst et al., 2005), INTACT -2 trial (Herbst et al., 2004), CALGB 30406 trial (Janne et al., 2012) and a randomized phase II by Hirsh et al (Hirsch et al., 2011), regardless of histology type, administration sequence, EGFR mutations status, whether patients was unselected or enriched population, and whether combining platinum or not. Thus we consider that combination antimitotube agents with EGFR-TKI may be not a good strategy for advanced NSCLC.

Acknowledgements
The study was supported by Beijing Natural Science Foundation (7142125). The authors declare that they have no competing interests.

References


receptor. Mol Cancer Ther, 9, 1647-56.

